Efficacy of Topical Insulin Eye Drops In Dry Eye Disease
DOI:
https://doi.org/10.51985/JBUMDC2025655Keywords:
Dry, disease, eye, insulin, topicalAbstract
Objective: To seesee( ASSESS/ EVALUATE)evaluate the treatment efficacy of topical insulin eye drops in patients suffering
from dry eye disease (DED) by assessing improvement in corneal epithelialization, conjunctival hyperemia and corneal
staining assessed before and after 3 months of therapy.
Study Design and setting: Prospective analytical study, Department of Oophthalmology, Combined Military Hospital
Lahore from January-June 2025.
Methodology: A total of 390 patients with dry eye disease received topical insulin drops 1 U/ml, one drop in each eye to
be taken 6 hourly for a total duration of 3 months. Primary variables studied were improvement in epithelial defects, corneal
staining and hyperemia by comparing before and after 3 months of topical insulin therapy.
Results: Median hyperemia grade before therapy was 3.00 (1.00) before therapy and it was 1.00 (0.00) when assessed after
treatment at 3 month follow-up (p<0.001). Similarly, median corneal staining grade showed median scores of 9.00 (1.00)
before therapy and scores were 5.00 (2.00) at the 3 months follow-up after end of topical insulin treatment (p<0.001).
Corneal epithelialization defect was improved by 50% in patient with mild, moderate and severe grading score before
therapy.
Conclusion: We conclude that topical insulin can be recommended as an effective first line management option in patients
with dry eye disease improving hyperemia, corneal staining and epithelial defects.
References
1. Sheppard J, Shen Lee B, Periman LM. Dry eye disease:
identification and therapeutic strategies for primary care
clinicians and clinical specialists. Ann Med. 2023;55(1):241-
52.
2. Kayal A. The physiology of tear film. Dry Eye Syndrome—
Modern Diagnostic Techniques and Advanced Treatments.
2022.
3. Cai Y, Wei J, Zhou J, Zou W. Prevalence and incidence of
dry eye disease in Asia: a systematic review and meta-analysis.
Ophthalmic Res. 2022;65(6):647-58.
4. Messmer EM. Pathophysiology of dry eye disease and novel
therapeutic targets. Exp Eye Res. 2022;217:108944.
5. Giannaccare G, Ghelardini C, Mancini A, Scorcia V, Di Cesare
Mannelli L. New perspectives in the pathophysiology and
treatment of pain in patients with dry eye disease. Journal of
Clinical Medicine. 2021;11(1):108.
6. Sekhon AS, He B, Iovieno A, Yeung SN. Pathophysiology of
corneal endothelial cell loss in dry eye disease and other
inflammatory ocular disorders. Ocul Immunol Inflamm.
2023;31(1):21-31.
7 Aniah Azmi N, Bastion M-LC. Short-Term Results of Trial
of Topical Insulin for Treatment of Dry Eyes in Diabetics.
Eye & Contact Lens. 2020;46:S25-S32. https://doi.org/
10.1097/ICL.0000000000000623
8 Cid-Bertomeu P, Vilaltella M, Martínez M, Mir M, Huerva
V. Topical Insulin for Ocular Surface Disease. J Ocul Pharmacol
Ther. 2024;40(4):204-14.
9. Cid-Bertomeu P, Vilaltella M, Martínez M, Mir M, Huerva
V. Topical Insulin for Ocular Surface Disease. J Ocul Pharmacol
Ther. 2024;40(4):204-14.
10. Gorimanipalli B, Khamar P, Sethu S, Shetty R. Hormones
and dry eye disease. Indian J Ophthalmol. 2023;71(4):1276-
84. https://doi.org/10.4103/IJO.IJO_2887_22
11. Kunboon A, Tananuvat N, Upaphong P, Wongpakaran N,
Wongpakaran T. Prevalence of dry eye disease symptoms,
associated factors and impact on quality of life among medical
students during the pandemic. Sci Rep. 2024;14(1):23986.
https://doi.org/10.1038/s41598-024-75345-w
12. Sall K, Foulks GN, Pucker AD, Ice KL, Zink RC, Magrath
G. Validation of a modified National eye Institute grading
scale for corneal fluorescein staining. Clinical ophthalmology.
2023:757-67.
13. Chauchat L, Guerin C, Sahyoun M, Guillon M, Calonge M.
Management of Oxidative Stress and Inflammation in Patients
with Symptomatic Dry Eye Disease Treated with a
Preservative-Free Ophthalmic Emulsion Combining AlphaLipoic Acid and High Molecular Weight Sodium Hyaluronate.
Adv Ther. 2025;42(5):2219-33. https://doi.org/10.1007/s12325-
025-03139-1
14. Abdi P, Ghaffari R, Azad N, Alshaheeb A, Latifi G, Soltani
Shahgoli S, Fakhredin H. Topical insulin for refractory
persistent corneal epithelial defects. Sci Rep. 2024;14(1):12459.
https://doi.org/10.1038/s41598-024-63091-y
15. Burgos-Blasco B, Diaz-Valle D, Rego-Lorca D, Perez-Garcia
P, Puebla-Garcia V, Fernandez-Vigo JI, et al. Topical insulin,
a novel corneal epithelial regeneration agent in dry eye disease.
Eur J Ophthalmol. 2024;34(3):719-25.
16. Zhang Q, Zhang H, Qin G, Wu Y, Song Y, Yang L, et al.
Impact of diquafosol ophthalmic solution on tear film and
dry eye symptom in type 2 diabetic dry eye: a pilot study. J
Ocul Pharmacol Ther. 2022;38(2):133-40.
17. de Oliveira Andrade LJ, Matos de Oliveira GC, Santos França
C, Matos de Oliveira L. Evaluating the Safety and Efficacy
of Topical Insulin for Ocular Disease: A Systematic Review.
medRxiv. 2024:2024.02. 24.24303321. https://doi.org/10.1101/
2024.02.24.24303321
18. Krolo I, Behaegel J, Termote K, de Bruyn B, De Schepper
M, Oellerich S, Dhubhghaill SN. The role of topical insulin
in ocular surface restoration: A review. Surv Ophthalmol.
2024.
19. Balal S, Din N, Ashton C, Ahmad S. Healing of chemical
injury–related persistent corneal epithelial defects with topical
insulin. Cornea. 2023;42(8):1000-4. https://doi.org/10.1097/I
CO.0000000000003145
20. Khilji M, Tanveer S, Khan FZ, Yazdan DA, Khilji A.
Neurotrophic keratopathy and topical insulin therapy: A case
report. Cureus. 2023;15(9). https://doi.org/ 10.7759/cureus.
46242
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Samar Fatima, Muhammad Jahanzaib , Khalid Baloch, Maeirah Shafique, Fakhar Humayun, Junaid Afsar (Author)

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Journal of Bahria University Medical & Dental College is an open access journal and is licensed under CC BY-NC 4.0. which permits unrestricted non commercial use, distribution and reproduction in any medium, provided the original work is properly cited. To view a copy of this license, visit https://creativecommons.org/licenses/by-nc/4.0